Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance
Immunis.AI
Summary
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Description
Efficient next generation RNA sequencing platforms have allowed for whole genome expression profiling of individual populations of immune cells as a novel means of searching for patterns of gene expression to aid in the identification of meaningful signals unique to various disease states. Single cell sequencing techniques have provided additional information useful in deconvolution strategies applied to model development on purified populations of immune cells. Recent interest in peripheral leukocyte subset gene expression profiles suggests that diagnostic information for many disorders may b…
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Patients \> 18 yrs of age. * Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy. * Patients undergoing screening mammograms for breast cancer. Exclusion Criteria: * Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer). * Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer. * Any biopsy which resulted in the entire tumor tissue being removed. * History of previous breast cancer. * Patients unable to provide informed consent. * Patients wi…
Interventions
- Diagnostic TestBlood test
Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
Location
- Duke UniversityDurham, North Carolina